Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
25.97
-0.64 (-2.41%)
At close: Jul 19, 2024, 4:00 PM
25.98
+0.01 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Myriad Genetics Employees
Myriad Genetics had 2,700 employees as of December 31, 2023. The number of employees increased by 100 or 3.85% compared to the previous year.
Employees
2,700
Change (1Y)
100
Growth (1Y)
3.85%
Revenue / Employee
$286,741
Profits / Employee
-$86,889
Market Cap
2.35B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,700 | 100 | 3.85% |
Dec 31, 2022 | 2,600 | 200 | 8.33% |
Dec 31, 2021 | 2,400 | -300 | -11.11% |
Jun 30, 2020 | 2,700 | 100 | 3.85% |
Jun 30, 2019 | 2,600 | 200 | 8.33% |
Jun 30, 2018 | 2,400 | 0 | - |
Jun 30, 2017 | 2,400 | 194 | 8.79% |
Jun 30, 2016 | 2,206 | 168 | 8.24% |
Jun 30, 2015 | 2,038 | 389 | 23.59% |
Jun 30, 2014 | 1,649 | 324 | 24.45% |
Jun 30, 2013 | 1,325 | 156 | 13.34% |
Jun 30, 2012 | 1,169 | 112 | 10.60% |
Jun 30, 2011 | 1,057 | 187 | 21.49% |
Jun 30, 2010 | 870 | 1 | 0.12% |
Jun 30, 2009 | 869 | -125 | -12.58% |
Jun 30, 2008 | 994 | 146 | 17.22% |
Jun 30, 2007 | 848 | 126 | 17.45% |
Jun 30, 2006 | 722 | 65 | 9.89% |
Jun 30, 2005 | 657 | 146 | 28.57% |
Jun 30, 2004 | 511 | -6 | -1.16% |
Jun 30, 2003 | 517 | 26 | 5.30% |
Jun 30, 2002 | 491 | 39 | 8.63% |
Jun 30, 2001 | 452 | 114 | 33.73% |
Jun 30, 2000 | 338 | 94 | 38.52% |
Jun 30, 1999 | 244 | -26 | -9.63% |
Jun 30, 1998 | 270 | 73 | 37.06% |
Jun 30, 1997 | 197 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fortrea Holdings | 19,000 |
QuidelOrtho | 7,100 |
Evolent Health | 4,700 |
Integra LifeSciences Holdings | 3,946 |
UFP Technologies | 3,093 |
Intellia Therapeutics | 526 |
Vericel | 314 |
Celldex Therapeutics | 160 |
MYGN News
- 10 days ago - Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing - GlobeNewsWire
- 19 days ago - Myriad Genetics Earns 2024 Great Place To Work® Certification™ - GlobeNewsWire
- 27 days ago - Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election - GlobeNewsWire
- 6 weeks ago - Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool - GlobeNewsWire
- 7 weeks ago - QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications - GlobeNewsWire
- 2 months ago - Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting - GlobeNewsWire
- 2 months ago - New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer - GlobeNewsWire
- 2 months ago - Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA - GlobeNewsWire